2025
24 November, 2025
Invitation to FluoGuide A/S (Nasdaq: FLUO) webcast on 27 November 2025
FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025. The following event will take place later that...
5 November, 2025
FluoGuide strengthens leadership to advance clinical program and regulatory approval strategy
Copenhagen, Denmark 4 November 2025 – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company...
5 November, 2025
FluoGuide convenes an extraordinary general meeting
Copenhagen, Denmark 4 November 2025 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby invites shareholders...
Copenhagen, Denmark, 3 November 2025 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that it...
FluoGuide A/S announces that two of its shareholders, both of whom hold management and/or board positions in the Company, have entered...
3 November, 2025
FluoGuide A/S completes directed share issue of SEK 104 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA...
3 November, 2025
FluoGuide A/S intends to carry out a directed share issue of approximately SEK 100 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA...
28 October, 2025
FluoGuide in advanced negotiations on collaboration agreement with a world leading medical technology company
Copenhagen, Denmark, 28 October 2025 – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company...
6 October, 2025
Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, presented at EANS
Copenhagen, Denmark, 6 October 2025 – FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech...
